New York, Feb 25, 2026, 05:57 EST — Premarket
- Tempus AI slipped roughly 4% ahead of the bell, following its Q4 numbers and 2026 outlook released late Tuesday.
- Company is now targeting 2026 revenue of approximately $1.59 billion, with adjusted EBITDA seen landing near $65 million.
- Q4 revenue jumped 83% to $367.2 million, with MRD test volume reaching roughly 4,700.
Tempus AI dropped 4.1% to $55.59 before the bell Wednesday, with investors reacting to the company’s 2026 outlook after its earnings release the day prior.
Shares ended Tuesday at $57.95, gaining 1.15%.
This report lands at a moment when Tempus stands out in a packed healthcare tech field—“AI” might draw the headlines, but it’s cash flow steering the share price. Investors want to see that strong test growth and data licensing can chip away at losses, and do it without fresh dilution.
Tempus is projecting revenue of roughly $1.59 billion for 2026, along with full-year adjusted EBITDA of about $65 million. That profit metric leaves out interest, taxes, depreciation and amortization.
Revenue jumped 83% to $367.2 million in the fourth quarter, with $266.9 million coming from diagnostics and $100.4 million from data and applications, the company reported. Stripping out the earlier Ambry acquisition, “organic” growth landed at 33.5%. Fast Edgar Archive
Founder and CEO Eric Lefkofsky pointed to “the strength of our unit growth in diagnostics” and highlighted the company’s accelerating data business, calling Tempus “unique in this space.” Nasdaq
MRD — short for minimal residual disease — caught investor attention. The test checks for lingering cancer cells after treatment. Tempus logged around 4,700 MRD tests last quarter, a 56% jump from the previous period.
Tempus flagged a few recent operating moves it says should fuel growth, such as its AI-driven digital pathology product and fresh clinical partnerships with major health systems.
Tempus filed its earnings release via Form 8-K and put up additional financial details, along with a letter from its CEO and CFO, on its investor relations page, according to a regulatory filing.
Still, net loss persisted for the quarter, with the company relying significantly on stock-based compensation—something that drags on per-share numbers despite revenue climbing. In its annual report, the firm lays out the usual diagnostics and data sector risks: competition, regulatory pressures, and the uncertain path of new product growth.
First comes the 9:30 a.m. EST open. After that, it’s all about what analysts do with their forecasts once the Feb. 24 release drops—either they raise estimates, or they decide the guidance doesn’t leave enough room for more gains, given how far the stock has already run lately.
